Anagenics Ltd (AN1) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Anagenics Ltd stock A$0.00, price A$0.01, that is 25.0% below the price, quality 47 out of 100. Rating: overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range A$0.0040 – A$0.1060 · the A$0.0060 price screens above the A$0.0045 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Anagenics in your weekly email
Every Wednesday you see whether Anagenics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name.
Show moreShow less
It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021.
Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
Stock analysis
Anagenics Ltd (AN1) currently trades at A$0.0060, while our model-based Fair Value estimate is A$0.0045, 25% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of A$0.0100 per share, and 13 of the 13 models we run sit above the A$0.0060 price.
Bear case: the DCF Models group reads lowest at A$0.0100, and 0 of the 13 models stay below the price. Data coverage for this calculation is low.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Anagenics Ltd reported revenue of A$5.2M in FY2026 versus A$6.9M in FY2022, a compound −7.2%/yr. Reported net income was A$308K in FY2026.
Key figures
Market cap A$5.6M (≈ $3.9M) Micro · P/S ratio 0.95 · Net margin 6.0% · Return on equity 10.2% · Return on assets (EBIT) −33.5% (5-year average) · Operating margin 7.3% · Revenue (TTM) A$5.2M · Revenue growth (YoY) +15.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −25%, AN1 screens cheaper than that median.
Fair Value models
BearA$0.0045Fair Value A$0.0045BullA$0.0045
Price A$0.0060 · Downside -25.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
ROIC CompounderA$0.0100A$0.0100A$0.010072
EPVn/aA$0.0100A$0.010070
Owner Earningsn/aA$0.0100A$0.020068
All 13 models by family
DCF Models
Owner Earningsn/aA$0.0100A$0.020068
Earnings-Based
Graham-Doddn/aA$0.0100A$0.020059
Lynch FVn/aA$0.0100A$0.010059
PEG = 1.0n/aA$0.0100A$0.010055
EPVn/aA$0.0100A$0.010070
Multiples
P/E Multiplen/aA$0.0100A$0.010060
P/S Multiplen/aA$0.0100A$0.010055
P/B Multiplen/aA$0.0100A$0.010052
EV/EBITA$0.0100A$0.0100A$0.010066
EV/EBITDAA$0.0100A$0.0100A$0.010067
EV/RevenueA$0.0100A$0.0100A$0.010054
Economic Profit
ROIC CompounderA$0.0100A$0.0100A$0.010072
Growth Earnings
Growth-Adj P/EA$0.0100A$0.0100A$0.010068
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Start year 2021 (pandemic). Over 10 years: +5.2% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−62.6% (2021) → 12.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Bottom 25%
Fair Value upside−25.0% · Below median
Profitability
Return on equity (12 months)10.2% · Above median
Return on assets6.5% · Above median
Net margin (12 months)6.0% · Above median
Operating margin (12 months)7.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)15.2% · Top 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B1.34× · Cheaper than median
P/S (12 months)1.09× · Cheaper than median
EV/EBITDA9.2× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 36
FUTURE (revenue growth)76· sector 20
PAST (return on equity)41· sector 31
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Anagenics Ltd Fair Value". https://www.fairvalue-calculator.com/stock/AN1
Frequently asked questions
Is Anagenics Ltd (AN1) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0045 versus a price of A$0.0060, about 25% lower (overvalued).
What is the fair value of AN1?
Our model-based fair value for Anagenics Ltd is A$0.0045 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0060.
What is the quality score of AN1?
Anagenics Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anagenics Ltd (AN1)?
Our model-based price target is the fair value of A$0.0045 (as of Nov 4, 2026) from 13 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Anagenics Ltd stock forecast for 2026?
Our models put fair value at A$0.0045, about 25% lower versus a price of A$0.0060 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Anagenics Ltd (AN1)?
Anagenics Ltd reported trailing-twelve-month revenue of about A$5.2M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Anagenics Ltd (AN1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anagenics Ltd it is A$0.0045 per share (as of Nov 4, 2026), against a price of A$0.0060. It is the blended result of 13 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Economic Profit, Growth Earnings).
Is Anagenics Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, AN1 trades above its calculated fair value: price A$0.0060, fair value A$0.0045, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AN1?
No. The price is what the market pays today (A$0.0060); the fair value is what the company's own numbers justify (A$0.0045). For Anagenics Ltd the two are A$0.0015 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anagenics Ltd worth?
The market values Anagenics Ltd at about A$5.6M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0060; our models calculate a fair value of A$0.0045 per share.
How solid is the balance sheet of Anagenics Ltd (AN1)?
Balance-sheet figures for Anagenics Ltd (as of Nov 4, 2026): return on equity 10.2%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is AN1 from its 52-week high?
Anagenics Ltd trades at A$0.0060, about 33% below its 52-week high of A$0.0090 and 20% above the low of A$0.0050 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0045 is for.
Which stocks are comparable to Anagenics Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anagenics Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0060, calculated fair value A$0.0045 (−25%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AN1 calculated?
We run Anagenics Ltd through 13 models from 5 families: DCF Models, Earnings-Based, Multiples, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$0.0045 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Anagenics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anagenics Ltd (AN1)?
The closing price on Nov 9, 2026 was A$0.0060. Our model-based fair value is A$0.0045, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anagenics Ltd right now?
The price sits above even our optimistic bull case (A$0.0045). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Anagenics Ltd
How large is the market capitalisation of Anagenics Ltd (AN1)?
The market capitalisation of Anagenics Ltd is A$5.6M (≈ $3.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anagenics Ltd (AN1)?
The price-to-sales ratio of Anagenics Ltd is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Anagenics Ltd (AN1)?
The net margin of Anagenics Ltd is 6.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anagenics Ltd (AN1)?
The return on equity (ROE) of Anagenics Ltd is 10.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anagenics Ltd (AN1)?
On an EBIT basis the return on assets of Anagenics Ltd is −33.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anagenics Ltd (AN1)?
The operating margin of Anagenics Ltd is 7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anagenics Ltd (AN1)?
Revenue at Anagenics Ltd is growing +15.2% versus a year earlier (3y avg −17.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Anagenics Ltd (AN1) generate?
The free cash flow of Anagenics Ltd is −A$1.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Anagenics Ltd (AN1) hold?
Anagenics Ltd holds more cash than debt, A$544K net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Anagenics Ltd in the live analysis
One click puts Anagenics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
